4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: BI 10773 high doseDrug: BI 10773 low doseDrug: placebo to BI 10773Drug: BI 10773 medium dose
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 78
- Registration Number
- NCT00558571
- Locations
- ๐ฉ๐ช
1245.4.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
๐ฉ๐ช1245.4.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
๐ฉ๐ช1245.4.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany
Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 156
- Registration Number
- NCT00558025
- Locations
- ๐ซ๐ท
248.636.3307C Boehringer Ingelheim Investigational Site, Bron cedex, France
๐ณ๐ฑ248.636.31005 Boehringer Ingelheim Investigational Site, 's-hertogenbosch, Netherlands
๐ซ๐ท248.636.3303B Boehringer Ingelheim Investigational Site, Aix en Provence, France
Filtered Trial for Amlodipine Non-responder
- Conditions
- Hypertension
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 531
- Registration Number
- NCT00558064
- Locations
- ๐ฏ๐ต
1235.13.009 Boehringer Ingelheim Investigational Site, Kiyose, Tokyo, Japan
๐ฏ๐ต1235.13.002 Boehringer Ingelheim Investigational Site, Sendai, Miyagi, Japan
๐ฏ๐ต1235.13.038 Boehringer Ingelheim Investigational Site, Kitaazumi-gun, Nagano, Japan
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: matching placebo twice daily (BID)
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1353
- Registration Number
- NCT00558259
- Locations
- ๐บ๐ธ
1160.63.01002 Boehringer Ingelheim Investigational Site, Laguna Hills, California, United States
๐บ๐ธ1160.63.01020 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
๐บ๐ธ1160.63.01032 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14956
- Registration Number
- NCT00557258
- Locations
- ๐ฉ๐ช
Boehringer Ingelheim Investigational Site, Zwickau, Germany
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 947
- Registration Number
- NCT00553267
- Locations
- ๐ง๐ฌ
1235.6.35904 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
๐ฎ๐ช1235.6.35304 Wilmer Road, Birr, Ireland
๐ง๐ฌ1235.6.35902 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 154
- Registration Number
- NCT00552240
- Locations
- ๐บ๐ธ
1100.1512.24 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
๐บ๐ธ1100.1512.20 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
๐บ๐ธ1100.1512.17 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
Filtered Trial for Telmisartan 40mg Non-responder
- Conditions
- Hypertension
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 314
- Registration Number
- NCT00550953
- Locations
- ๐ฏ๐ต
1235.14.003 Boehringer Ingelheim Investigational Site, Musashino, Tokyo, Japan
๐ฏ๐ต1235.14.002 Boehringer Ingelheim Investigational Site, Chofu, Tokyo, Japan
๐ฏ๐ต1235.14.004 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
Observational Non-interventional Study With Viramuneยฎ in Combination With Truvadaยฎ in HIV-infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 334
- Registration Number
- NCT00543803
- Locations
- ๐ฉ๐ช
Boehringer Ingelheim Investigational Site, Wuppertal, Germany
๐ฉ๐ชBoehringer Ingelheim Investigational Site 1, Stuttgart, Germany
๐ฉ๐ชBoehringer Ingelheim Investigational Site 10, Berlin, Germany
Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1296
- Registration Number
- NCT00540163
- Locations
- ๐ฉ๐ช
Boehringer Ingelheim Investigational Site, Zossen, Germany